Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ClearBridge SMID Cap Growth strategy initiates new positions, exits several in Q1 [Seeking Alpha]
A Look At Mirum Pharmaceuticals (MIRM) Valuation After Strong Long Term Share Performance [Yahoo! Finance]
Mirum Pharmaceuticals (MIRM) had its price target raised by TD Cowen from $117.00 to $125.00. They now have a "buy" rating on the stock.
Mirum Pharmaceuticals (MIRM) had its "buy" rating reaffirmed by HC Wainwright. They now have a $130.00 price target on the stock.